Table 2.
Clinical characteristics of Parkinson’s disease patients with mild to moderate and severe non-motor symptoms burden
| PD mild to moderate NMS burden (NMSS = 0–40) | PD severe NMS burden (NMSS ≥ 41) | |
|---|---|---|
| No (%) | 23 (56.1%) | 18 (43.9%) |
| Gender (M, %) | 15 (65.2%) | 9 (50%) |
| Age (years; median ± SD) | 58.5 ± 8.9 | 70.3 ± 8.3* |
| Disease durationa (months; median ± SD) | 16.1 ± 60.4 | 108.0 ± 73.8* |
| Daily LED (mg; median ± SD) | 250.3 ± 438.3 | 690.0 ± 1219.6* |
| H&Y OFF (median ± SD) | 1.0 ± 0.8 | 2.3 ± 1.2* |
| MMSE (median ± SD) | 30.0 ± 1.6 | 29.5 ± 1.3 |
| PDQ-39 (median ± SD) | 9.5 ± 16.1 | 47.0 ± 24.4*** |
H&Y Hoehn & Yahr, LED levodopa equivalent dose, MMSE mini mental status examination, NMSS Non-motor Symptoms Scale, PDQ-39 39-item Parkinson’s disease Questionnaire, UPDRS-III Unified Parkinson’s Disease Rating Scale part III
*P < 0.05; ***P < 0.001
aFrom time of first appearance of Parkinson’s disease motor symptoms